	US 11,952,328 B2
	Selective ship inhibitors for treating disease
William G. Kerr, Syracuse, NY (US); and John D. Chisholm, Fayetteville, NY (US)
Assigned to THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, Syracuse, NY (US)
Filed by THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, Syracuse, NY (US); and SYRACUSE UNIVERSITY, Syracuse, NY (US)
Filed on Oct. 17, 2019, as Appl. No. 16/656,284.
Claims priority of provisional application 62/746,793, filed on Oct. 17, 2018.
Prior Publication US 2020/0277256 A1, Sep. 3, 2020
Int. Cl. C07C 309/47 (2006.01); A61P 35/00 (2006.01); C07D 241/04 (2006.01); C07D 243/08 (2006.01); C07D 275/06 (2006.01); C07D 471/10 (2006.01); C07D 487/10 (2006.01)

CPC C07C 309/47 (2013.01) [A61P 35/00 (2018.01); C07D 241/04 (2013.01); C07D 243/08 (2013.01); C07D 275/06 (2013.01); C07D 471/10 (2013.01); C07D 487/10 (2013.01)]

3 Claims

1. A method for inhibiting a SH2-containing inositol 5′-phosphatase 1 (SHIP 1) in a subject comprising administering to the subject an effective amount of 8-((2-aminoethyl)amino)naphthalene-1-sulfonic acid, or a pharmaceutically acceptable salt.